- |||||||||| alteminostat (CKD-581) / Chong Kun Dang
Trial completion: Safety and Pharmacokinetic Profile of CKD-581 (clinicaltrials.gov) - Oct 5, 2016 P1, N=39, Completed, Recruiting --> Completed | Trial primary completion date: Jun 2011 --> Jan 2014 Recruiting --> Completed
- |||||||||| dexamethasone / Generic mfg., bendamustine / Generic mfg., pomalidomide / Generic mfg.
Clinical: Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma (clinicaltrials.gov) - Sep 27, 2016 P1/2, N=56, Active, not recruiting, N=200 --> 155 | Recruiting --> Terminated; Five immune related serious adverse events Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016
- |||||||||| bortezomib / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Autophagy Induction After Bortezomib for Myeloma (clinicaltrials.gov) - Sep 26, 2016 P0, N=11, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Active, not recruiting | N=15 --> 11 | Trial primary completion date: Apr 2016 --> Jun 2015
- |||||||||| Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Trial completion, Enrollment change, Trial primary completion date: Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma (clinicaltrials.gov) - Sep 23, 2016 P1/2, N=11, Completed, Recruiting --> Active, not recruiting | N=15 --> 11 | Trial primary completion date: Apr 2016 --> Jun 2015 Active, not recruiting --> Completed | N=55 --> 11 | Trial primary completion date: May 2017 --> Sep 2016
- |||||||||| Enrollment change, Trial primary completion date: Comprehensive Frailty Assessment (clinicaltrials.gov) - Sep 22, 2016
P=N/A, N=111, Active, not recruiting, Not yet recruiting --> Enrolling by invitation | Initiation date: Nov 2015 --> Mar 2016 N=400 --> 111 | Trial primary completion date: Nov 2016 --> Jun 2017
- |||||||||| melphalan / Generic mfg., clarithromycin / Generic mfg.
Enrollment change, Trial termination: CLAIM: Clarithromycin in Multiple Myeloma Induction Therapy (clinicaltrials.gov) - Sep 20, 2016 P2, N=58, Terminated, Recruiting --> Active, not recruiting N=160 --> 58 | Recruiting --> Terminated; Suspected side effects to the combination of clarithromycin and VCD (bortezomib, cyclophosphamide and dexamethasone)
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi
Enrollment closed, Enrollment change: Collection of Transplant Stem Cells for Plasma Cell Myeloma (clinicaltrials.gov) - Sep 16, 2016 P2, N=49, Active, not recruiting, Active, not recruiting --> Completed | N=36 --> 15 | Trial primary completion date: Aug 2016 --> May 2016 Recruiting --> Active, not recruiting | N=70 --> 49
- |||||||||| BeneFix (nonacog alfa) / Pfizer
Trial primary completion date: BeneFIX Drug Use Results Survey [All-Case Surveillance] (clinicaltrials.gov) - Sep 9, 2016 P=N/A, N=314, Completed, Recruiting --> Active, not recruiting | N=21 --> 12 Trial primary completion date: May 2014 --> Aug 2014
- |||||||||| Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial completion, Enrollment change: Interleukin-2 Treatment for Wiskott-Aldrich Syndrome (clinicaltrials.gov) - Sep 6, 2016 P1, N=9, Completed, Trial primary completion date: Oct 2016 --> Mar 2017 Recruiting --> Completed | N=15 --> 9
- |||||||||| DCR-MYC / Novo Nordisk
Enrollment closed, Metastases: Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma (clinicaltrials.gov) - Sep 1, 2016 P1, N=74, Active, not recruiting, Trial primary completion date: Dec 2016 --> Dec 2018 Recruiting --> Active, not recruiting
- |||||||||| Empliciti (elotuzumab) / AbbVie, BMS
Phase classification, Trial primary completion date, Combination therapy: A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma (clinicaltrials.gov) - Aug 31, 2016 P1b/2, N=102, Active, not recruiting, Recruiting --> Active, not recruiting Phase classification: P2 --> P1b/2 | Trial primary completion date: Nov 2016 --> Dec 2013
|